Occuity COO, Mark Jenkins and Head of Marketing, Richard Kadri-Langford head to Barcelona to showcase the PM1 and AX1 at ESCRS 2024

Recent developments in Alzheimer's treatment have ignited both hope and critical discussion in the medical community and within the wider...

Following our great success last year in Vienna, we are pleased to announce that Occuity will again be available for meetings, this time...

Occuity has some great news on our recently filed patents. We’ve now heard that 3 of our new patents have received a “notice of intent to...

Occuity Secures Second Future Leaders Fellowship Award Occuity is thrilled to announce that Dr. Emily J. Patterson has been awarded a...

We are thrilled to announce that Jamie Serjeant, one of our talented engineers, has been honoured with the prestigious RAEng Engineers...

Occuity shortlisted for the LIFE SCIENCES & HEALTH TECH COMPANY OF THE YEAR at the Thames Valley Tech Awards 2024

We’re delighted to announce that Occuity has been selected as a finalist for the Hard Tech Investment of the Year award at the...

World Council of Optometry (WCO) has teamed up with CooperVision to launch an innovative tool designed to set a new standard in myopia manag

We are proud to announce that Occuity has been named the "Medtech & Healthtech StartUp of the Year" in the South East at the UK Startup...

As we observe Myopia Awareness Week, it is crucial to highlight the rapid growth of myopia, also known as short-sightedness, and the...

It was widely reported yesterday, that the commonly used HbA1c test for diagnosing and monitoring Type 2 diabetes, has been found to potenti

Last week, I packed up some PM1s and one of our AX1 prototypes and headed to the Excel centre in London for this years 100% Optical, the...

In the ever-evolving landscape of healthcare, the role of ocular diagnostics in detecting systemic diseases is gaining prominence....

Occuity is delighted to announce its third consecutive attendance at 100% Optical, Europe's fastest-growing optical event. As we move...

As we approach the end of 2023, it's a fitting time to reflect on Occuity's progress throughout the year. Looking back, it's clear that...

We're very pleased to announce the successful completion of our Convertible Loan Note (CLN) investment round, which reached its target of...

Occuity is pleased to announce the filing of a new patent covering our novel approach to detecting and quantifying biomarkers in the eye....

We are pleased to announce a key milestone in Occuity's technology development strategy has been achieved. One of our recent patents,...

Occuity has recently unveiled an exciting partnership with Indo Optical, a multinational corporation boasting over seven decades of...